Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy

• Published in: Movement disorders Vol. 22; no. 12; pp. 1822 - 1824
• Main Authors: Martinez-Rodriguez, Jose Enrique, Seppi, Klaus, Cardozo, Adriana, Iranzo, Alex, Stampfer-Kountchev, Michaela, Wenning, Gregor, Tolosa, Eduardo, Högl, Birgit, Santamaria, Joan, Poewe, Werner
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.09.2007; Wiley
• Subjects: Aged; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Female; Humans; hypocretin; Intracellular Signaling Peptides and Proteins - cerebrospinal fluid; Male; Medical sciences; Middle Aged; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; multiple system atrophy; Multiple System Atrophy - cerebrospinal fluid; Multiple System Atrophy - physiopathology; Neurology; Neuropeptides - cerebrospinal fluid; orexin; Orexins; Multiple system atrophy; hypocretin; Nervous system diseases; Cerebrospinal fluid; orexin
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.21668

Hypocretin (orexin) cerebrospinal fluid (CSF) levels have been previously found normal or decreased in Dementia with Lewy bodies and Parkinson disease, two synucleinopathies commonly associated with excessive daytime sleepiness (EDS). We evaluated CSF hypocretin‐1 levels in 15 patients with moderately severe multiple system atrophy (MSA), another synucleinopathy where sleep disorders occur frequently and EDS has been reported, performing additional electrophysiological studies in 5 of them to assess the presence of EDS and sleep onset REM (SOREM) periods. Despite relatively low sleep efficiencies in nocturnal sleep, mean sleep latencies in the Multiple Sleep Latency Test were normal with no SOREM periods. All patients had CSF hypocretin‐1 levels in the normal range (>200 pg/mL) suggesting that the hypocretin system is not altered in MSA, at least in patients with a moderately severe disease. © 2007 Movement Disorder Society